Alderaan Biotechnology

Paris based company – France

Alderaan Biotechnology develops antibodies directed against immune cells for the treatment of cancers. The first program is dedicated to the development of IL2-sparing, CD25-specific antibodies allowing Regulatory T cells (Tregs) depletion in tumours. The second program is focused on NK cell modulation using antibodies specific for CD160-TM, a new NK cell activating receptor.

https://alderaan-biotechnology.com/

AdBio partners contact: Matthieu Coutet

Agomab Therapeutics

Gent based company – Belgium

Agomab Therapeutics develops agonistic antibodies targeting the receptor c-MET that recapitulate the regenerative and anti-inflammatory properties of the ligand HGF.

https://agomab.com/

AdBio partners contact: Matthieu Coutet

Arthex Biotech

Valence based company – Spain

ARTHEx Biotech develops antisense technologies targeting miR-23b and miR-218 for the treatment of Myotonic Dystrophy type 1 (DM1).

https://arthexbiotech.com/

AdBio partners contact: Alain Huriez

Augustine Therapeutics

Leuven based company – Belgium

Augustine Therapeutics is leading two drug discovery programs to identify new selective HDAC6 inhibitors and GABABR1a agonists for the treatment of neurological diseases such as Charcot Marie Tooth disease and peripheral neuropathies. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin repair.

https://augustinetx.com/

AdBio partners contact: Alain Huriez

Depth Charge

Paris based company – France

Depth Charge Therapeutics develops novel immune oncology agents for tumour-selective modulation of the microenvironment.

AdBio partners contact: Geoffroy de Ribains

DiogenX

Marseille based company – France

DiogenX is developing new compounds for beta cells regeneration for the treatment of type-1 diabetes.

https://diogenx.com

AdBio partners contact: Matthieu Coutet

Integra Therapeutics

Barcelona based company – Spain

Integra Therapeutics develops a proprietary gene editing platform for in vivo and ex vivo permanent gene editing.

https://integra-tx.com/

AdBio partners contact: Matthieu Coutet

Kalsiom

Brest based company – France

Kalsiom develops first-in-class antibodies targeting calcium signaling for the treatment of auto-immune diseases.

AdBio partners contact: Geoffroy de Ribains

Ribonexus

Paris based company – France

Ribonexus is developing small molecules targeting eif4F complex in cancer.

AdBio partners contact: Matthieu Coutet

SparingVision

Paris based company – France

SparingVision develops gene therapy treatments for patients affected by Inherited Retinal Diseases, regardless of genetic cause.

https://sparingvision.com/

AdBio partners contact: Geoffroy de Ribains

Thabor Therapeutics

Rennes based company – France

Thabor Therapeutics develops innovative treatments based on monoclonal antibodies for human mucosal inflammatory diseases.

AdBio partners contact: Alain Huriez

Tridek-One

Paris based company – France

Tridek-One develops a first-in-class monoclonal antibody that maintains clusters of truncated CD31 to the membrane. This original approach has a high therapeutic potential for a diversity of auto-immune and inflammatory disorders.

https://tridekone.com/

AdBio partners contact: Alain Huriez

Univercells

Brussels based company – Belgium

Global life sciences company offering best-in-class biomanufacturing infrastructure.

https://www.univercells.com/

AdBio partners contact: Alain huriez

Urania Therapeutics

Strasbourg based company – France

Urania Therapeutics is developing a unique structure-based drug discovery platform for the generation of new readthrough compounds to treat cancer and rare diseases.

https://uraniatx.com/

AdBio partners contact: Geoffroy de Ribains

Yukin Therapeutics

Nice based company – France

Yukin Therapeutics develops small molecules that inhibit the non-canonical NF-κB2 pathway. These new compounds have the potential to inhibit cancer cell proliferation and to massively modulate the tumour micro-environment.

AdBio partners contact: Matthieu Coutet

Calida Therapeutics

Location : Paris based company

Calida Therapeutics develops a first-in-class approach to address thrombo-inflammation and vascular diseases

AdBio partners contact: Alain Huriez